Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

7.490 +0.100 (+1.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 608,640
Open 7.390
Bid (Size) 7.050 (1)
Ask (Size) 7.600 (50)
Prev. Close 7.390
Today's Range 7.220 - 7.495
52wk Range 3.280 - 8.850
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Therapeutics's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q3, Esperion Therapeutics's (NASDAQ:ESPR) reported sales totaled $18.98 million. Despite a 16.9% increase in earnings, the company posted a loss of $55.12... 
Via Benzinga

Performance

YTD
+44.32%
+44.32%
1 Month
-9.87%
-9.87%
3 Month
-0.40%
-0.40%
6 Month
+28.47%
+28.47%
1 Year
+33.51%
+33.51%

More News

Read More
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Recap: Esperion Therapeutics Q3 Earnings
Via Benzinga
Esperion Therapeutics: Q2 Earnings Insights
Via Benzinga
Esperion Therapeutics: Q1 Earnings Insights
Via Benzinga
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Hosting Virtual Research & Development Day
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
Via Benzinga
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Wednesday's Surge
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Esperion Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2022
Via Benzinga
73 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.